Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BOLT

BOLT - Bolt Biotherapeutics, Inc. Stock Price, Fair Value and News

$6.71-0.38 (-5.36%)
Market Closed

63/100

BOLT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

63/100

BOLT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$8.52

Target 3M

$7.1

Target 6M

$7.54

BOLT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BOLT Price Action

Last 7 days

7.0%

Last 30 days

24.7%

Last 90 days

17.1%

Trailing 12 Months

-32.2%

BOLT RSI Chart

BOLT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BOLT Valuation

Market Cap

12.9M

Price/Earnings (Trailing)

-0.3

Price/Sales (Trailing)

2.48

Price/Free Cashflow

-0.19

BOLT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$8.52

Target 3M

$7.1

Target 6M

$7.54

BOLT Fundamentals

BOLT Revenue

Revenue (TTM)

5.2M

Rev. Growth (Yr)

90.1%

Rev. Growth (Qtr)

20.23%

BOLT Earnings

Earnings (TTM)

-42.7M

Earnings Growth (Yr)

52.93%

Earnings Growth (Qtr)

16.55%

BOLT Profitability

Return on Equity

-132.96%

Return on Assets

-65.61%

Free Cashflow Yield

-525.05%

BOLT Investor Care

Shares Dilution (1Y)

0.30%

Diluted EPS (TTM)

-22.29

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20253.6M4.2M5.2M0
202411.3M11.2M9.8M7.7M
20236.7M6.8M7.2M7.9M
20222.2M3.5M4.8M5.7M
20210269.0K970.0K1.4M
2020000257.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Bolt Biotherapeutics, Inc.

BOLT
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
 CEO
 WEBSITEboltbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES94

Bolt Biotherapeutics, Inc. Frequently Asked Questions

BOLT is the stock ticker symbol of Bolt Biotherapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Bolt Biotherapeutics, Inc. is 12.88 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check BOLT's fair value in chart for subscribers.

The fair value guage provides a quick view whether BOLT is over valued or under valued. Whether Bolt Biotherapeutics, Inc. is cheap or expensive depends on the assumptions which impact Bolt Biotherapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BOLT.

As of Wed Jan 28 2026, BOLT's PE ratio (Price to Earnings) is -0.3 and Price to Sales (PS) ratio is 2.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BOLT PE ratio will change depending on the future growth rate expectations of investors.